Since PEG3 was demonstrated as a biomarker of Mek/Erk/ROS/mTOR-driven hepatocarcinogenesis in response to KrasG12D mutation and Tsc1 insufficiency in murine models, we attempted to determine whether this biomarker was also applicable to HCC patients. Here, MTOR is linked to hepatocellular carcinoma.